Platform
Assembly of functional collagen requires specialized cellular machinery: multi-step post-translational modification, folding, secretion and fibril assembly. Mammalian cells already have it. We built the process around them.
01
Using cells from a small tissue biopsy, we create immortalized cell lines selected for maximum collagen production and consistent performance at scale.
02
Through optimization of culture media, the cellular micro-environment and other factors, we have radically boosted collagen production yields from these cells.
03
We designed a linearly scalable bioreactor system tailored for collagen that minimizes consumable costs and maximizes protein yield.
04
An efficient, scalable purification method delivers high-quality collagen while minimizing cost and time to product.
A platform for proteins simpler organisms cannot make
Plants, bacteria and yeast lack the cellular machinery to fold, modify and assemble large mammalian proteins correctly. Our mammalian cell platform does what they cannot: it produces real, native human proteins at scale.
By starting with collagen type I, one of the largest and most structurally demanding human proteins, we have validated a process that can extend to other complex targets across human biology.
Why this is hard
Recombinant microbial
E. coli and yeast
Prints peptide fragments or single chains. No triple helix, no native function.
Animal derived
Bovine, porcine, marine
Wrong species. Immunogenic, disease risk, batch variability.
Cadaver and tissue
Placenta, donor skin
Truly human, but unscalable, inconsistent and screened donor by donor.
Cellular agriculture
Jellatech
Real human cells in bioreactors. Native folding. Consistent, pharmaceutical-grade supply.